Zhongyin Biotech Completes New Financing Round to Advance Ophthalmic Gene Therapy Development and Files IPO Prospectus

According to a press release from CHIGENOVO, the funds raised in this round will be used to deeply advance the clinical and industrialization process of the company's drug pipeline, and to accelerate the market launch of its self-developed ophthalmic gene therapy drugs. CHIGENOVO is committed to the development of gene therapy drugs for hereditary eye diseases. The company currently has seven ongoing hereditary eye disease gene therapy pipelines, aiming to bring light and hope to patients with hereditary eye diseases worldwide. Among them, ZVS101e Injection is CHIGENOVO’s gene replacement therapy drug under research for Bietti's Crystalline Dystrophy (BCD), intended for the treatment of BCD patients carrying CYP4V2 gene mutations. It has been granted Orphan Drug Designation by the US FDA and completed the enrollment of the first subject in a phase 1/2 clinical trial in February this year.